RUSFER / ANNUAL
No resting orders on this market.
Important information: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Rusfertide, developed by Protagonist Therapeutics and licensed to Takeda, is a peptide drug designed to treat polycythemia vera (PV), a blood disorder in which the body overproduces red blood cells, causing the blood to thicken — much like a highway becoming dangerously congested. It works by reducing the need for a painful and burdensome procedure called therapeutic phlebotomy, which is a regular blood-letting used to keep red blood cell levels under control, and early trial data showed it could essentially eliminate that procedure for many patients.
Resolves Yes if the FDA's decision on Rusfertide by Protagonist Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Rusfertide, developed by Protagonist Therapeutics and licensed to Takeda, is a peptide drug designed to treat polycythemia vera (PV), a blood disorder in which the body overproduces red blood cells, causing the blood to thicken — much like a highway becoming dangerously congested. It works by reducing the need for a painful and burdensome procedure called therapeutic phlebotomy, which is a regular blood-letting used to keep red blood cell levels under control, and early trial data showed it could essentially eliminate that procedure for many patients.